RecruitingPhase 2NCT07037420

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Studying Acromegaly

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alexion Pharmaceuticals, Inc.
Intervention
ALXN2420(drug)
Enrollment
60 enrolled
Eligibility
18-80 years · All sexes
Timeline
20252027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07037420 on ClinicalTrials.gov

Other trials for Acromegaly

Additional recruiting or active studies for the same condition.

See all trials for Acromegaly

← Back to all trials